Business Context and Reporting Period
Company: REGENXBIO Inc. (RGNX)
Filing Type: Form 8-K (Current Report)
Date of Report: September 10, 2021
Event: Entry into a Material Definitive Agreement (Collaboration and License Agreement) with AbbVie Global Enterprises Ltd. to develop and commercialize RGX-314, a gene therapy candidate for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases.
Key Financial Metrics and Deal Terms
This filing details a strategic partnership rather than periodic financial results. Key financial terms include:
- Upfront Payment: $370.0 million to be received from AbbVie.
- Milestone Payments: Eligible to receive up to $1.38 billion in aggregate development, regulatory, and commercial milestones.
- Development and Regulatory: $782.5 million.
- Commercial: Remainder of the $1.38 billion total.
- Royalties: Tiered royalties on net sales outside the United States at percentages in the mid-teens to low twenties.
- Expense Allocation:
- Through December 31, 2022: REGENXBIO responsible for certain ongoing trial expenses; parties share additional development expenses.
- Beginning January 1, 2023: AbbVie responsible for the majority of development expenses.
- Profit Sharing: Net profits and losses from U.S. commercialization will be shared equally. AbbVie bears sole cost for commercialization outside the U.S.
Material Changes and Operational Impact
The agreement represents a material shift in the development and commercialization strategy for RGX-314:
- Development Scope: Parties must use commercially reasonable efforts to develop products for wet AMD (suprachoroidal and subretinal delivery) and DR in the U.S., with potential for an additional indication upon milestone achievement.
- Manufacturing: REGENXBIO will lead manufacturing for clinical development and U.S. commercial supply. AbbVie will lead manufacturing for commercial supply outside the U.S.
- Commercialization: REGENXBIO will participate in U.S. commercialization per a future plan. AbbVie will handle all commercialization outside the U.S.
Guidance, Risks, and Contingencies
Conditions Precedent: The agreement is effective only upon satisfaction of customary closing conditions, including the expiration of waiting periods under the Hart-Scott Rodino Antitrust Improvements Act and other competition laws.
Termination Rights: The agreement includes provisions for termination by:
- REGENXBIO upon a challenge of certain licensed patents by AbbVie.
- Either party for uncured material breach or insolvency of the other.
- AbbVie for convenience or safety reasons.
Forward-Looking Statements: The filing contains forward-looking statements regarding the collaboration and future operations, which are subject to risks and uncertainties. Actual results may differ materially from projections.
Investor Verification Checklist
- Verify the closing of the transaction and satisfaction of antitrust waiting periods.
- Confirm the receipt of the $370.0 million upfront payment in the next quarterly report (Form 10-Q).
- Review the specific development plan and commercialization plan to be determined under the agreement.
- Monitor the allocation of development expenses post-December 31, 2022, to ensure AbbVie assumes the majority of costs as agreed.
- Assess the impact of the royalty term (10-12 years post-first sale depending on region) on long-term revenue projections.